Global Brain has invested in Metaphore Biotechnologies, Inc. (Metaphore), a developer of an AI-powered drug discovery platform for functional antibodies, through its TOHO Ventures. Metaphore is a next-generation antibody therapeutics company founded by Flagship Pioneering, a US-based VC firm. Metaphore’s proprietary AI drug discovery platform MIMIC™ distinguishes itself from traditional structure-dependent approaches by designing antibodies starting from biological functions. The platform performs integrated AI analysis of large-scale functional data obtained from live cells alongside dynamic protein interaction information. This unique approach enables the creation of agonist and multi-functional antibodies, which have historically been difficult to design using structural data alone. With its core strengths in molecular optimization speed and high-potency design capabilities, Metaphore is currently advancing a pipeline with multiple programs in disease areas with high unmet medical needs, aiming to create the next generation of antibody therapeutics. Global Brain has decided to invest in Metaphore, highly valuing its unique function-oriented drug discovery philosophy powered by advanced AI and its accomplished team of scientists and executives. Through this investment, Global Brain will work together with TOHO HOLDINGS CO., LTD. to support Metaphore’s growth over the medium to long term.

About Metaphore

Location: Massachusetts, US
CEO: Angela Hwang
Founded: 2021
URL: https://metaphorebio.com/

About TOHO Ventures

Name: TOHO-GB Global Life Science Fund, L.P.
Fund Size: JPY 10 billion
Fund Term: 10 years
General Partner: Global Brain Corporation
Limited Partner: TOHO HOLDINGS CO., LTD.

About Global Brain

Location: Tokyo, Japan
Representative: Yasuhiko Yurimoto
Founded: January 1998
URL: https://globalbrains.com

Global Brain has invested in Metaphore Biotechnologies, Inc., a developer of an AI-powered drug discovery platform for functional antibodies